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genesis” in which the basics of transgenic and knockout
technology were outlined, and some novel mouse mod-
els with relevance to viral pathogenesis were described
(Rall and Oldstone, 1996). At that time, the selection of
models for inclusion in this chapter was reasonably
straightforward because the concept of transgenic and
knockout mice was fairly new, and few laboratories had
easy access to such methodologies. The dramatic in-
crease in the use of genetically modified mouse models
over the past 4 years has been enhanced by many
technological advances. For example, the conditional
expression or ablation of genes of interest using Cre/
loxP recombination, the specific isolation of cells of in-
terest from tissues with laser capture microdissection,
the use of tetramer assays to precisely quantify antigen-
specific lymphocytes, and the application of microarrays
to assess gene expression profiles in whole organs have
all contributed to the increased sophistication of the
questions being pursued with genetically engineered
mice.
Manipulating the genetics of a complex organism
such as a mouse has particular utility for the study of
viral pathogenesis. Understanding how a virus causes
disease necessarily involves an appreciation of how the
virus interacts with its host cell, the consequences of
infection to the tissue, and the role played by the host
immune response in both clearance and associated im-
munopathology. Moreover, other factors—including age,
gender, and genetic background—may contribute to vi-
rus-induced disease that can only be observed in vivo.
his review focuses on four applications of transgenic
nd knockout mouse technology that have been useful
or gaining insight into virus–host interactions. Each is
ighlighted with specific examples (Fig. 1). Of course, all
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220of the existing genetically engineered mouse models
with relevance to virus–host interactions cannot be dis-
cussed in this brief review; the interested reader is re-
ferred to a website that provides a comprehensive and
frequently updated list of published transgenic and
knockout mouse models (http://tbase.jax.org).
EXPRESSION OF HUMAN VIRUS RECEPTORS IN
TRANSGENIC MICE
The pathogenesis of many viruses that pose a signif-
icant public health threat, including the hepatitis viruses,
papillomavirus, polio, HIV-1, and measles, cannot be eas-
ily studied because mice are not normally susceptible to
infection by these viruses. Identification and cloning of
the human receptors for some of these viruses made it
possible to create receptor-expressing transgenic mice.
As discussed below, the establishment of such receptor
transgenics to date has been crucial to pathogenesis
studies of some viruses, but frustrating for studies in
others.
Polio
In 1990, following the identification of the human po-
liovirus (PV) receptor (PVR/CD155), the laboratories of
Racaniello (Ren et al., 1990) and Nomoto (Koike et al.,
1991) independently established transgenic mice that
ubiquitously expressed this receptor. Following an intra-
cerebral PV challenge, these mice became infected and
developed the paralytic disease associated with the hu-
man infection. This was a remarkable finding, since it
was not intuitive that simply expressing the receptor on
otherwise refractory cells would render those cells sus-
ceptible. Indeed, these mice continue to be of value and
in the past 2 years alone have been used to show (i) that
PV spreads from the periphery to the central nervous
system (CNS) by retrograde axonal transport (Arita et al.,
1999; Ohka et al., 1998), (ii) that neuronal receptor density
is a critical parameter of polio-induced paralysis (Deatly
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221MINIREVIEWet al., 1999), and (iii) that the well-characterized viral
nternal ribosome entry site (IRES) helps to govern PV
europathogenesis (Gromeier et al., 1999; Shiroki et al.,
1997). In addition to providing insights into PV pathogen-
esis, PVR mice were used to identify and characterize
the exogenous class I major histocompatibility complex
(MHC) presentation pathway (Sigal et al., 1999), the pro-
cess by which antigen-presenting cells that are not tar-
gets for certain viruses (including polio) still are able to
activate antiviral cytotoxic T lymphocytes (CTL).
Interestingly, however, one major difference between
humans and PVR transgenic mice is the route of infec-
tion. In humans, PV is transmitted orally and likely gains
access to the host by replicating in the M cells of the
small intestine (Minor, 1996), although oral PV adminis-
tration to PVR transgenic mice does not lead to subse-
quent infection. A recent report (Zhang and Racaniello,
1997) showed that receptor density in the gut was not the
basis for the block in PVR mice; rather, other factors,
including perhaps the need for a cofactor for viral entry
into intestinal cells or the inability of these cells to sup-
port the correct posttranslational modifications to the
PVR, may be involved in restricting viral replication in the
mouse intestine.
Human immunodeficiency virus-1 (HIV-1)
The success of the PVR transgenic mice resulted in
attempts to establish a mouse model for other viral
pathogens whose host range was limited to humans and
higher primates. One such effort was to create mice that
were susceptible to HIV-1 infection; expression of the
CD4 receptor alone failed, which in retrospect made
FIG. 1. Our present understanding of how viruses cause disease has
been greatly facilitated by the development of mouse models. Both
virus models and immune models have been established and ex-
ploited. Virus models include the expression of virus receptors, ge-
nomes, or individual proteins in transgenic mice; immune models
include both transgenic and knockout strategies to express or delete
specific chemokines and cytokines or to create mice with “clonal” T cell
receptors via the expression of TCR transgenes.sense, given the subsequent finding that HIV-1 requires
a coreceptor for entry (Feng et al., 1996). Renewed efforts fto establish doubly transgenic mice that express both
CD4 and CCR5, one of the chemokine receptors that also
serves as an HIV-1 coreceptor, were successful in allow-
ing viral entry of macrophage-tropic HIV isolates (Brown-
ing et al., 1997). However, subsequent replication and
pread did not occur, indicating that “postentry” differ-
nces between mouse and human cells exist which limit
IV-1 replication in murine cells.
easles
Efforts to establish transgenic models for human mea-
les virus (MV) infection have been more successful.
hile MV can be controlled by an efficacious vaccine, it
emains a significant cause of mortality (.1 million/year)
n developing countries, owing mainly to opportunistic
nfections acquired during a period of transient immuno-
uppression in acutely infected individuals. Moreover,
V can result in rare but often fatal diseases of the CNS,
ncluding subacute sclerosing panencephalitis (SSPE), a
isease of children associated with massive neuronal
ropout, glial cell activation, immune cell infiltration, and
lood–brain barrier damage.
Several recent efforts to express the human MV re-
eptor, CD46, in transgenic mice have provided a clearer
nderstanding of the basis of MV-induced immune sup-
ression and CNS disease. The first of such models
xpressed CD46 under the control of a neuron-specific
romoter (NSE), in an effort to parallel aspects of human
SPE by allowing MV infection of CNS neurons (Rall et
l., 1997). Infection and CNS disease in NSE–CD46 mice
as age-dependent; transgenic neonates succumbed
hile adults were protected (Rall et al., 1997). Subse-
uent backcrossing to established immune knockout
ice allowed for the determination of the T cell subsets
hat contributed to protection in adults (Lawrence et al.,
999) and provided insights into the disease that occurs
n neonates (Lawrence et al., 1999; Manchester et al.,
999). A similar critical role for immune control in MV
nfection was shown using a yeast artificial chromosome
YAC) to express the CD46 gene; in this model, the
ercentage of transgenic mice that became infected and
eveloped disease dramatically increased when these
ice were intercrossed with interferon alpha/beta recep-
or knockout mice (Mrkic et al., 1998).
Receptor transgenic mice can also be of value for the
stablishment of susceptible primary cells for studying
spects of viral replication and spread. For example,
rimary neurons cultured from NSE–CD46 embryos were
he basis of a recent report which demonstrated that
pread of MV in neurons, distinct from the classical
ytopathic and productive infection of nonneuronal cells,
ikely occurs by transsynaptic transmission (Lawrence et
l., 2000).A successful effort to establish a “whole mouse” model
or MV infection was accomplished recently, again using
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222 MINIREVIEWa YAC containing the CD46 gene (Oldstone et al., 1999).
In this system, immunocompetent mice developed an
age-dependent CNS disease similar to that seen in the
NSE–CD46 system. Moreover, MV-infected YAC–CD46
mice produced recoverable infectious virus from lympho-
cytes, which importantly was associated with both hu-
moral and cellular immune suppression (Oldstone et al.,
999). This in vivo model of immunosuppression in an
otherwise immunocompetent host will be useful not only
to gain a clearer understanding of the basis for MV-
induced immunosuppression, but also for studying the
replication and spread of viral mutants and the testing of
novel MV vaccines.
Interestingly, not all transgenic models that express
CD46 have resulted in mice that can be infected in vivo.
For example, expression of CD46 under the control of the
ubiquitously expressed hydroxymethyl-glutaryl coen-
zyme A reductase (HMGCR) promoter resulted in effi-
cient CD46 expression in vivo and the ability to infect
primary cells cultured from such mice, but did not allow
for productive infection of transgenic mice after MV chal-
lenge (Horvat et al., 1996). While this model system did
not display the phenotype originally expected, such mod-
els may be of value in identifying the cellular factors that
limit virus infection in vivo.
EXPRESSION OF VIRAL GENOMES IN
TRANSGENIC MICE
For viruses in which the human receptor has yet to be
identified (e.g., hepatitis B virus) or for which receptor
expression is insufficient to allow viral replication (e.g.,
HIV-1), virus–host issues can still be studied by express-
ing the viral genome under the transcriptional control of
either the viral promoter or a heterologous promoter.
However, expression of the entire virus or viral proteins
during development usually results in immune tolerance,
complicating studies of virus–immune interactions. Two
successful approaches to study virus–immune interac-
tions in such transgenic mice are discussed below, as
well as a comment on the recent application of cre/loxP
technology to conditionally express a human hepatitis C
virus transgene.
Hepatitis B virus (HBV)
Transgenic mice expressing the human HBV genome
were established to parallel both the transient and the
chronic infections of humans (Guidotti et al., 1994). In this
system, because HBV is expressed throughout develop-
ment resulting in immune tolerance, exogenously edu-
cated T cells are inoculated into HBV transgenic mice in
order to study virus–immune response interactions.
Adoptive transfer of activated anti-HBV CTLs resulted in
a rapid elimination of virus from the liver, although the
mechanism of such clearance was surprisingly not
through “classical” CTL-mediated target cell lysis. Rather,
t
athese CTL mediated their antiviral effects through the
expression of cytokines, specifically interferon gamma
(IFN-g) and tumor necrosis factor alpha (TNF-a) (Guidotti
et al., 1994). This anti-HBV effect can even be induced by
liver infection with an unrelated virus, since antilympho-
cytic choriomeningitis virus (LCMV) CTL were also able
to noncytolytically clear HBV replication intermediates
from the transgenic liver (Guidotti et al., 1996). Chisari
and colleagues have used this system to show that
CTL-elaborated cytokines exert this “intracellular virus
inactivation” effect via two mechanisms: elimination of
HBV nucleocapsid particles and destabilization of viral
RNAs (Guidotti et al., 1999; Tsui et al., 1995).
To observe the induction of the naive host response to
HBV, a recent report (Larkin et al., 1999) described the
expression of an HBV transgene in severe combined
immunodeficient (scid) mice. Reconstitution of a func-
tional immune response in these mice was then accom-
plished by the adoptive transfer of MHC-matched,
unprimed splenocytes; such a transfer resulted in clear-
ance of virus from the liver and development of a chronic
hepatitis (Larkin et al., 1999). Thus, with this system, the
education and recruitment of a naive immune response
can be evaluated in a murine model system.
Hepatitis C virus (HCV)
The advent of cre/loxP technology has allowed for the
expression of the Cre recombinase that permits the con-
ditional excision or insertion of the targeted DNA at any
stage of development, including adults. A modification of
this approach was reported (Wakita et al., 1998) in which
the Cre recombinase, provided by a nonreplicating ade-
novirus vector, activated an integrated HCV transgene.
Although no infectious virus was produced in this sys-
tem, serum core protein and hepatocyte immunostaining
were detected after delivery of the Cre recombinase, and
expression of the virus was accompanied by activation
and infiltration of CD41 and CD81 T cells into the liver.
hus, the controlled temporal expression of a transgene
ore closely parallels the natural infection and will be a
owerful approach to evaluating antiviral immunity in
mmunocompetent hosts.
EXPRESSION OF INDIVIDUAL VIRAL GENES
Many laboratories have utilized transgenic ap-
roaches to express individual viral genes in mice to
xamine the contributions of such genes to the patho-
enesis of the parent virus. In transgenic efforts not
iscussed further in this review, previously identified viral
ncogenes (e.g., SV40 large T antigen) have been usedo study issues of oncogenesis; the reader is referred to
n excellent review of such systems (Furth, 1998).
c223MINIREVIEWHIV-1
While efforts to establish models of HIV-1 infection by
receptor expression on mouse cells have not resulted in
susceptible mice, the expression of individual HIV-1 pro-
teins has provided some insights into the basis of HIV-1
damage. HIV can enter the human CNS and contribute to
both cognitive and motor impairments in infected indi-
viduals. Interestingly, microglia are the primary cellular
target within the brain, though the most profound pathol-
ogy is associated with neuronal damage. How does
infection of one cell type cause death of another? Previ-
ously, the expression of the HIV-1 surface glycoprotein,
gp120, in astrocytes was shown to induce neuronal de-
generation and synaptic density loss similar to that ob-
served in the human infection (Toggas et al., 1994). Re-
cent efforts with this model system have shown that
gp120, expressed on glial cells, induces matrix metallo-
proteinase activity that may exacerbate extracellular ma-
trix degradation (Marshall et al., 1998), thereby contrib-
uting to neuronal loss.
Epstein–Barr virus (EBV)
EBV has been associated with Burkitt’s lymphoma, a
cancer primarily of children. Despite the exclusive ex-
pression of the EBV nuclear antigen-1 (EBNA-1) gene
product in such tumors, no in vitro studies conclusively
demonstrated that this protein was responsible for main-
tenance of the tumor state. Transgenic mice that ex-
pressed the EBNA-1 protein targeted to B cells showed
that expression of this protein alone was sufficient to
transform B lymphocytes and result in splenomegaly
(Wilson et al., 1996). What is particularly interesting about
this report is the speculation of why such a striking
difference between in vitro studies and the transgenic
mice would exist: the authors suggest that the EBNA-1
protein interferes with the progression of B cell develop-
ment. If the infected B cells were blocked at the point of
immunoglobulin gene rearrangement, this could stall the
developing lymphocytes in a continuously cycling stage,
predisposing the infected host to lymphomagenesis.
Mouse mammary tumor virus (MMTV)
For both the HIV-1 and EBV models described above,
viral proteins are expressed in transgenic mice, although
transgenic methodology can also be used to discern the
function of nontranslated regions of the viral genome.
MMTV is a natural pathogen of mice which infects both
the lactating mammary gland and lymphoid tissue during
its infectious cycle. However, certain endogenous
MMTVs are only transcribed in lymphoid tissue. Ross
and colleagues (Qin et al., 1999) identified an endoge-
nous viral mutant that possessed a single amino acid
change within the untranslated long terminal repeat
(LTR); this mutation was sufficient to convert an other-wise lymphoid-specific endogenous virus to a milk-
borne, infectious virus. Confirmation of the relevance of
this single residue change was demonstrated by the
establishment of transgenic mice expressing the original
and mutated forms of the LTR driving expression of the
reporter gene, chloramphenicol acetyl transferase (CAT).
This report then demonstrated preferential binding of the
transcription factors Stat5a and Stat5b to the mutated
LTR, which allowed for expression in the mammary
gland.
Transgenic models of autoimmunity
Finally, transgenic mice expressing viral genes have
been used to elucidate basic features of human autoim-
mune diseases that may be associated with virus infec-
tions, such as insulin-dependent diabetes mellitus
(IDDM) and multiple sclerosis (MS). The development
and utility of such mouse models have been extensively
reviewed (Herrath et al., 1996). In brief, transgenic ex-
pression of the LCMV nucleoprotein (NP) in the beta
cells of the pancreatic islets of Langerhans did not result
in any overt effect until such mice were challenged with
LCMV. Following virus challenge, NP-expressing mice
developed a massive anti-LCMV response that also re-
sponded to the “self” NP expressed in the islets, leading
to marked increases in blood sugar and eventual death
of the mice (Ohashi et al., 1991; Oldstone et al., 1991). A
similar situation occurred when LCMV NP was targeted
to oligodendrocytes of the CNS, the primary target of
demyelination in diseases such as multiple sclerosis
(Evans et al., 1996). In both systems, the authors are not
proposing that LCMV is responsible for these human
diseases; rather, these models demonstrate that homol-
ogy between viral proteins and self proteins could allow
an otherwise helpful antiviral effect to turn against the
host, respond to the similar self protein, and result in an
autoaggressive response. This concept, known as mo-
lecular mimicry (Oldstone, 1998), was recently shown to
occur in humans (Zhou et al., 1998).
INFECTION OF MICE WITH ALTERED
IMMUNE RESPONSES
In addition to the development of transgenic models
that express viral proteins and receptors, a large number
of mice with genetically altered immune responses exist.
Immune knockout mice have been established with de-
letions of either specific cell populations or immune
mediators, such as cytokines and chemokines. Exam-
ples of the former include TCR-b knockouts that lack T
ells, mMT mice that lack B cells, and RAG-1 knockouts
that lack both. As described earlier in this review, direct
infection of such mice, or infection of receptor transgen-
ics intercrossed with such cellular knockouts, has led to
the identification of immune cell subsets that are critical
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224 MINIREVIEWfor resolution of a number of viruses, including measles,
LCMV, and influenza.
A classic example of an immune mediator knockout
with direct relevance to viral pathogenesis is the perforin
knockout mouse, developed by Zinkernagel and col-
leagues (Kagi et al., 1994). Perforin is a molecule en-
oded by CTL and natural killer (NK) cells that punctures
he plasma membrane of a target cell, allowing entry of
ytolytic granules into the target cell cytoplasm. Prior to
he establishment of these mice, the belief that CTL
ysed their targets in vivo was extrapolated from the
bility of activated CTL to lyse target cells in in vitro
hromium release assays. In mice genetically deficient
or the perforin gene, the importance of perforin for CTL
unction was confirmed: the absence of perforin, even in
he presence of an otherwise intact immune response,
endered perforin-deficient mice unable to clear an
CMV challenge, supporting the requirement of perforin
or the resolution of noncytopathic virus infections. Im-
ortantly, negative data obtained from immune knockout
ice can also be informative: using the same perforin
nockout system, investigators reported that perforin
as dispensable for the clearance of murine gammaher-
esvirus 68 (MHV-68), Semliki Forest virus, influenza
irus, and vesicular stomatitis virus (VSV) (Usherwood et
l., 1997).
Transgenic technology has also been exploited to de-
elop immunologically altered mice. Mice that express T
ell receptor transgenes are used to assess the effect of
pecific immune cell populations on viral clearance. For
xample, it is well known that CD81 CTL play a major
role in elimination of LCMV from infected mice; less is
known about the role of CD41 T helper cells. To deter-
ine the effect of CD41 T cells on viral clearance and
heir role in the generation of the antibody response,
ice were established that expressed a CD41 T cell
eceptor specific for a class II MHC-restricted LCMV
pitope (Oxenius et al., 1998). This strategy is usually
uite effective in generating mice with T cell specificities
estricted to the transgene, likely because the presence
f the TCR transgene prevents subsequent T cell rear-
angements from occurring. Despite high levels of
CMV-specific CD41 T cells, such mice succumbed to
LCMV challenge, compared to the robust and diverse
immune response that protects normal mice. These data
reinforced the notion that the existence of abundant,
virus-specific immune cells is not sufficient to confer
protection; rather, different immune effectors must be
present to confer protective immunity.
Transgenic mice have also been valuable in charac-
terizing both the protective and deleterious effects of
soluble immune mediators, including cytokines. For ex-
ample, transgenic mice in which the cytokine IFN-a was
verexpressed in CNS astrocytes were able to survive
n otherwise lethal intracerebral LCMV challenge, likely
hrough a direct ability of the IFN-a transgene to sup-press viral replication. However, such mice also sponta-
neously developed a progressive inflammatory enceph-
alopathy, reflecting the subtle balance between immune-
mediated protection and immunopathology (Akwa et al.,
1998).
Conversely, the use of transgenics expressing virus
proteins can be used to gain a deeper understanding of
the role of the host immune response and its role in viral
pathogenesis. HSV-1, which typically infects nerve cells,
can also infect lymphocytes. Interestingly, transgenic ex-
pression of HSV-1 in lymphocytes resulted in a rapid
elimination of antiviral T cells by apoptotic “fratricide,”
which the authors speculated plays a major role in al-
lowing HSV-1 to evade the immune response and persist
in the infected host (Raferty et al., 1999).
Finally, virus infection of mice of different MHC haplo-
types can reveal much about the ability of a virus to
mediate disease. Coxsackie B virus infection induces an
inflammation of cardiac tissue in certain strains of mice.
Huber and colleagues (Huber et al., 1999) demonstrated
that such strain-specific susceptibility was attributable to
differences in the MHC class II haplotype that was ac-
companied by substantial differences in the gamma–
delta T cell repertoire. Such differences may alter the T
helper profile (Th1 vs Th2) of infected mice and directly
affect whether this animal can clear the virus challenge
or develop lethal myocarditis.
FUTURE PERSPECTIVE
Those of us in the field of viral pathogenesis often
lament that it is a challenging discipline: infection of
genetically identical mice with the same dose of virus
often leads to frustratingly different outcomes. We usu-
ally ascribe such variability to the complexity of working
with living systems: by infecting mice, we are infecting a
vessel that is difficult to control. Immune responses, host
age, genetic background, and perhaps even gender can
skew how a mouse responds to a given viral pathogen.
Yet the mouse is also a remarkably simplistic model for
human diseases: the use of inbred strains in controlled
environments does not take into account the genetic and
environmental factors that certainly play key roles in
human virus infections. In particular, for virus studies we
often use mice that have not been previously exposed to
other pathogens; thus, the response we observe does
not take into account the important role of an organism’s
immune history.
Nevertheless, the studies that have been completed to
date using genetically engineered mouse models have
allowed for remarkable insights in a relatively brief pe-
riod of time. There is little doubt that with the advent of
sequence-verified mouse cDNA libraries for use in gene
chip arrays, the completion of the mouse genome
project, and the progressively more sophisticated appli-
cation of conditional gene expression or deletion, trans-
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225MINIREVIEWgenic and knockout mouse models will remain a funda-
mental source of information about viruses and they
diseases they cause.
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